Vitrolife Q4’2020: Very strong Numbers.
Redeye's first impression of the fourth-quarter report. Sales amounted to SEK 382, a decrease of 7% in SEK. Thus, very much in line with our expected SEK 378m. The Covid-19 continues to affect sales, but there is a clear business return and not as harsh as earlier.
EBIT was also considerably higher than we and the street expected at SEK 147m vs. our expected SEK 121m. (Estimated consensus SEK 129m).